Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374750 | 1.00 | KMT2A (0.68) | KMT2AMAPK1PABPC1POLBHRH2 | |
| SCHEMBL10421620 | 0.92 | KMT2A (0.59) | KMT2AMAPK1PABPC1POLBHRH2 | |
| SCHEMBL6162477 | 0.89 | KMT2A (0.71) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL6162815 | 0.89 | KMT2A (0.71) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL6162484 | 0.89 | KMT2A (0.71) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL27014496 | 0.88 | POLB (0.61) | KMT2AMAPK1POLB | |
| SCHEMBL2374758 | 0.87 | KMT2A (0.68) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL2374766 | 0.87 | KMT2A (0.68) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL4900321 | 0.87 | KMT2A (0.67) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL5408063 | 0.87 | KMT2A (0.67) | KMT2AMAPK1PABPC1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | KMT2A 515/4885MAPK1 3730/4885PABPC1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.